Abstract: Described is the use in the treatment of either male or female sexual dysfunction of selective antagonists of the ?1B-adrenergic receptor and the pharmaceutical compositions containing them as compounds capable of helping the sexual act avoiding at the same time excessive side effects due to acute hypotension.
Type:
Grant
Filed:
August 22, 2001
Date of Patent:
October 11, 2005
Assignees:
Recordati S.A. Chemical, Pharmaceutical Company
Inventors:
Amedeo Leonardi, Gianni Motta, Rodolfo Testa, Giorgio Sironi
Abstract: The present invention relates to substituted heteroaromatic compounds, methods for their preparation, pharmaceutical compositions containing them and their use in medicine. Specifically, the invention relates to quinazoline derivatives useful in treating disorders mediated by protein tyrosine kinase activity, in particular erbB-2 and/or EGFR activity.
Type:
Grant
Filed:
February 8, 2002
Date of Patent:
March 30, 2004
Assignee:
SmithKline Beecham Corporation
Inventors:
Malcolm Clive Carter, George Stuart Cockerill, Stephen Barry Guntrip, Karen Elizabeth Lackey, Kathryn Jane Smith
Abstract: There are provided novel compounds of formula (I) ##STR1## including their 3,4-dihydropyrimidine tautomer form, wherein R.sup.1, R.sup.2, R.sup.3, R.sup.4, R.sup.5, X and n are as defined in the specification, and optical isomers and racemates thereof and pharmaceutically acceptable salts thereof; together with processes for their preparation, compositions containing them and their use in therapy. The compounds are antagonists of N-type neuronal calcium channels useful in the treatment of cerebrovascular ischaemia and pain.
Type:
Grant
Filed:
October 14, 1998
Date of Patent:
May 2, 2000
Assignee:
Astra Aktiebolag
Inventors:
William F. Michne, M. Edward Pierson, Jr.
© 2024 Justia
